Program
Hyaluronic Acid
Also written as “sodium hyaluronate 0.18%”, “Sodium hyaluronate” and “sodium hyaluronate”.
Its studies are mostly in Dry Eye Syndromes · Osteoarthritis, Knee · Osteoarthritis · Gingivitis · Keratoconjunctivitis Sicca, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Laboratorios Sophia S.A de C.V. | 40 open or running | phase 4since Jan 7, 2021 | Sep 4, 2019 | none ahead |
| AbbVie | 30 open or running | phase 4since Sep 25, 2008 | Sep 25, 2008 | none ahead |
| Sanofi | 30 open or running | phase 4since Aug 12, 2005 | Aug 12, 2005 | none ahead |
| Daiichi Sankyo | 10 open or running | phase 3since May 23, 2006 | May 23, 2006 | none ahead |
| IBSA Institut Biochimique | 11 open or running | phase 3since Sep 9, 2026 | Sep 9, 2026 | Jun 30, 2027phase 3 · NCT07819461 |
| KLSMC Stem Cells | 10 open or running | phase 2since Mar 24, 2017 | Mar 24, 2017 | none ahead |
| Kunming Baker Norton Pharmaceutical Sales | 10 open or running | phase 4since Jun 27, 2016 | Jun 27, 2016 | none ahead |
| Lantibio | 10 open or running | phase 3since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Liquidia Technologies | 10 open or running | phase 1since Nov 22, 2016 | Nov 22, 2016 | none ahead |
| TRB Chemedica | 10 open or running | phase 2since Dec 23, 2010 | Dec 23, 2010 | none ahead |
Also a collaborator on its studies: Premier Research Group and River Plate Biotechnology.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Aug 12, 2005.
- Sep 14, 2006Phase 3 study in Osteoarthritis of ShoulderSanofi · NCT00377624 · 602 enrolled · United States
- Jan 11, 2008Lantibio's first study: phase 3 study in Dry Eye SyndromesNew to LantibioLantibio · NCT00599716 · 300 enrolled · United States
- Sep 25, 2008AbbVie's first study: phase 4 study in Dry Eye SyndromesNew to AbbVieAbbVie · NCT00761202 · 50 enrolled · United Kingdom
- Jan 21, 2009Phase 4 study in OsteoarthritisSanofi · NCT00830830 · 40 enrolled · United States
- Jul 10, 2009Phase 4 study in Dry Eye SyndromesAbbVie · NCT00938704 · 71 enrolled · Germany
- Dec 23, 2010TRB Chemedica's first study: phase 2 study in Osteoarthritis, KneeNew to TRB ChemedicaTRB Chemedica · NCT01267214 · 40 enrolled · Thailand
- Apr 16, 2014Phase 4 study in Dry Eye SyndromesAbbVie · NCT02117687 · 80 enrolled · France, United Kingdom
- Jun 27, 2016Kunming Baker Norton Pharmaceutical Sales's first study: phase 4 study in Osteoarthritis, KneeNew to Kunming Baker Norton Pharmaceutical SalesKunming Baker Norton Pharmaceutical Sales · NCT02826031 · 300 enrolled · China
- Nov 22, 2016Liquidia Technologies's first study: phase 1 study in Acute PainNew to Liquidia TechnologiesLiquidia Technologies · NCT02982889 · 29 enrolled · Denmark
- Mar 24, 2017KLSMC Stem Cells's first study: phase 2 study in Articular Cartilage Disorder of KneeNew to KLSMC Stem CellsKLSMC Stem Cells · NCT03101163 · 120 enrolled · United States, Malaysia
- Sep 4, 2019Laboratorios Sophia S.A de C.V.'s first study: phase 1 study in Dry Eye SyndromesNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT04081610 · 34 enrolled · Mexico
- Jan 7, 2021Phase 2 study in Dry Eye SyndromesLaboratorios Sophia S.A de C.V. · NCT04704531 · 141 enrolled · Mexico
- Jan 7, 20212 phase 4 studiesLaboratorios Sophia S.A de C.V. · NCT04704518, NCT04702776
- Sep 9, 2026IBSA Institut Biochimique's first study: phase 3 study in Osteoarthritis, KneeNew to IBSA Institut BiochimiqueIBSA Institut Biochimique · NCT07819461 · 704 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Osteoarthritis, KneeIBSA Institut Biochimique · NCT07819461
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07819461Osteoarthritis, Knee | 3 | Not yet recruiting | IBSA Institut Biochimique | Jun 30, 2027 | 704 |
| NCT04704531Dry Eye Syndromes · Mexico | 2 | Completed | Laboratorios Sophia S.A de C.V. | Jun 8, 2022 | 141 |
| NCT04704518Photorefractive Keratectomy · Mexico | 4 | Completed | Laboratorios Sophia S.A de C.V. | Dec 22, 2023 | 96 |
| NCT04702776Dry Eye Syndromes · Mexico | 4 | Completed | Laboratorios Sophia S.A de C.V. | May 15, 2023 | 182 |
| NCT04081610Dry Eye Syndromes · Mexico | 1 | Completed | Laboratorios Sophia S.A de C.V. | Oct 23, 2019 | 34 |
| NCT03101163Articular Cartilage Disorder of Knee · United States, Malaysia | 2 | Completed | KLSMC Stem Cells | Jul 2022 | 120 |
| NCT02982889Acute Pain · Denmark | 1 | Completed | Liquidia Technologies | Mar 23, 2017 | 29 |
| NCT02826031Osteoarthritis, Knee · China | 4 | UNKNOWN | Kunming Baker Norton Pharmaceutical Sales | Oct 2017 | 300 |
| NCT02117687Dry Eye Syndromes · France, United Kingdom | 4 | Completed | AbbVie | Jan 27, 2015 | 80 |
| NCT01267214Osteoarthritis, Knee · Thailand | 2 | Completed | TRB Chemedica | Feb 2010 | 40 |
| NCT00938704Dry Eye Syndromes · Germany | 4 | Completed | AbbVie | Jun 2009 | 71 |
| NCT00830830Osteoarthritis · United States | 4 | Completed | Sanofi | 40 | |
| NCT00761202Dry Eye Syndromes · United Kingdom | 4 | Completed | AbbVie | Jun 2008 | 50 |
| NCT00599716Dry Eye Syndromes · United States | 3 | Completed | Lantibio | Apr 2008 | 300 |
| NCT00377624Osteoarthritis of Shoulder · United States | 3 | Completed | Sanofi | 602 | |
| NCT00330135Osteoarthritis, Hip · France | 3 | Terminated | Daiichi Sankyo | Mar 2007 | 85 |
| NCT00130468Osteoarthritis · United States | 4 | Completed | Sanofi | 150 |
How it is read
Names in the registry
- “sodium hyaluronate 0.18%”, 2 entries
- “Sodium hyaluronate”, 2 entries
- “sodium hyaluronate”, 2 entries
- “Hyalgan (sodium hyaluronate)”, 2 entries
- “Sodium hyaluronate solution - 3.36%”, 1 entry
Codes read as this program: PRO037.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 6 studies
- Osteoarthritis, Knee, 3 studies
- Osteoarthritis, 3 studies
- Gingivitis, 1 study
- Keratoconjunctivitis Sicca, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.